Pulmatrix (NSDQ:PULM) today priced an underwritten public offering of 23,500,000 units, including one share of common stock, one Series A warrant to buy one share of common stock and one Series B warrant to buy one share of common stock per unit.
The Lexington, Mass.-based company also gave underwriters a 30-day option to buy an additional 1,150,000 units. Pulmatrix reported that it expects to bring in approximately $15.2 million from the offering.
Get the full story at our sister site, Drug Delivery Business News.
